Literature DB >> 2829433

TPA-inducible Epstein-Barr virus genes in Raji cells and their regulation.

G Laux1, U K Freese, R Fischer, A Polack, E Kofler, G W Bornkamm.   

Abstract

A number of agents including the tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA) can induce an abortive virus cycle in the EBV nonproducer Burkitt's lymphoma line Raji. We describe the pattern of viral RNAs transcribed in uninduced cells and in cells treated with TPA for 8 hr, as analyzed by Northern blotting. By comparing the patterns of RNAs observed in cells treated with TPA, TPA plus cycloheximide, or cycloheximide alone, we have tested whether any EBV gene in TPA-treated Raji cells would be inducible directly by TPA in the presence of protein synthesis inhibitors, similarly to immediate-early genes induced by superinfection of Raji cells with P3HR-1 virus in the presence of cycloheximide. We demonstrate here that induction of all early EBV genes is dependent on ongoing protein synthesis. The experiments do not provide an answer to whether TPA acts by activating an initial step in the cascade of virus production or whether TPA has a simultaneous pleiotropic effect on the regulation of a large number of viral genes.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2829433     DOI: 10.1016/0042-6822(88)90496-5

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  25 in total

1.  Identification of a novel element involved in regulation of the lytic switch BZLF1 gene promoter of Epstein-Barr virus.

Authors:  R J Kraus; S J Mirocha; H M Stephany; J R Puchalski; J E Mertz
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

2.  Inhibition of S-phase cyclin-dependent kinase activity blocks expression of Epstein-Barr virus immediate-early and early genes, preventing viral lytic replication.

Authors:  Ayumi Kudoh; Tohru Daikoku; Yutaka Sugaya; Hiroki Isomura; Masatoshi Fujita; Tohru Kiyono; Yukihiro Nishiyama; Tatsuya Tsurumi
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

3.  The Epstein-Barr virus R transactivator (Rta) contains a complex, potent activation domain with properties different from those of VP16.

Authors:  J M Hardwick; L Tse; N Applegren; J Nicholas; M A Veliuona
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

4.  Transcriptional synergy by the Epstein-Barr virus transactivator ZEBRA.

Authors:  M Carey; J Kolman; D A Katz; L Gradoville; L Barberis; G Miller
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

5.  Negative regulation of the BZLF1 promoter of Epstein-Barr virus.

Authors:  E A Montalvo; Y Shi; T E Shenk; A J Levine
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

6.  Efficient transcription of the Epstein-Barr virus immediate-early BZLF1 and BRLF1 genes requires protein synthesis.

Authors:  E K Flemington; A E Goldfeld; S H Speck
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

7.  De novo protein synthesis is required for lytic cycle reactivation of Epstein-Barr virus, but not Kaposi's sarcoma-associated herpesvirus, in response to histone deacetylase inhibitors and protein kinase C agonists.

Authors:  Jianjiang Ye; Lyndle Gradoville; Derek Daigle; George Miller
Journal:  J Virol       Date:  2007-06-27       Impact factor: 5.103

8.  Immunofluorescence microscopy and flow cytometry characterization of chemical induction of latent Epstein-Barr virus.

Authors:  H B Jenson; G M Grant; Y Ench; P Heard; C A Thomas; S G Hilsenbeck; M P Moyer
Journal:  Clin Diagn Lab Immunol       Date:  1998-01

9.  The cellular YY1 transcription factor binds a cis-acting, negatively regulating element in the Epstein-Barr virus BRLF1 promoter.

Authors:  S Zalani; A Coppage; E Holley-Guthrie; S Kenney
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

10.  Expression of the BZLF1 latency-disrupting gene differs in standard and defective Epstein-Barr viruses.

Authors:  N Taylor; J Countryman; C Rooney; D Katz; G Miller
Journal:  J Virol       Date:  1989-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.